Drugs Made In America Acquisition Corp. Ordinary Shares Cash Flow-to-Debt Ratio
Drugs Made In America Acquisition Corp. Ordinary Shares cash flow-to-debt ratio. Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a Cash Flow-to-Debt Ratio of -0.03x as of June 2026, meaning its operating cash flow of $-244.61K could theoretically repay 0% of its total liabilities ($9.14 Million) in one year. Check Drugs Made In America Acquisition Corp. earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2025)
Cash flow-to-debt ratio of Drugs Made In America Acquisition Corp. Ordinary Shares from 2024 to 2025. Historical debt coverage capacity for Drugs Made In America Acquisition Corp. Ordinary Shares across 2 annual periods. Check how aggressively does Drugs Made In America Acquisition Corp. reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Drugs Made In America Acquisition Corp. Ordinary Shares Cash Flow-to-Debt Ratio by Year (2024–2025)
Drugs Made In America Acquisition Corp. Ordinary Shares cash flow-to-debt ratio by year from 2024 to 2025. Year-by-year debt coverage analysis for Drugs Made In America Acquisition Corp. Ordinary Shares. For the full cash flow conversion analysis, see Drugs Made In America Acquisition Corp. (DMAA) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.07x | $-539.19K | $7.28 Million | ▲ +100.0% |
| 2024 | -216.50x | $-172.26K | $795.67 | — |